An elite, structurally-advantaged WFE franchise riding the most powerful capex secular in a generation — wrapped in a multiple that has already discounted the bull case. The franchise is a 5; the entry point is a 3.
The thesis in one paragraph. Lam Research is the world's #1 etch franchise (~45% share) and #2 in deposition, sitting at the exact physics chokepoints — 3D-NAND high-aspect-ratio etch, gate-all-around, advanced packaging, molybdenum ALD, EUV dry resist — where the AI-driven WFE supercycle is most intense. TTM revenue of $21.7B is compounding ~25%, gross margin has structurally re-rated to ~50%, and the company returns 85%+ of FCF. This is a punch-the-table business. The problem is the price: at $326.71 the stock trades at ~41× FY27 EPS, ~18× sales and ~50× EBITDA — a full AI re-rate that leaves the probability-weighted 12-month target ($313) below spot, and even the sell-side mean ($313) marginally negative. We own the franchise on cyclical pullbacks toward the $230–260 zone (where the CFO was a seller and a published street DCF sits at $170); at $327 the risk/reward is balanced-to-poor.
1 · Etch/deposition intensity inflection. NAND 300→1,000 layers, GAA (+15–20% etch steps), backside power and HBM/advanced packaging all raise Lam's dollar-content-per-wafer faster than wafer-start growth.
2 · The CSBG annuity. 100,000+ installed chambers generate $8.2B TTM of higher-margin recurring spares/service revenue — a structural margin and stability anchor.
3 · Margin + capital-return compounding. GM guided to 50.5%, OM to 36.5% — already beating the 2028 model — on Malaysia footprint + mix, funding ~$10B buybacks.
1 · Valuation / cyclicality collision. A cyclical at ~50× EBITDA prices zero air-pocket. WFE is not a secular-straight-line; any digestion year compresses both E and the multiple.
2 · China. 34% of revenue, normalizing toward sub-30% on export controls, while Naura/AMEC take domestic share (China WFE share 6.5% and rising).
3 · Memory concentration. DRAM/NAND swing the model; HBM is a positive but NAND wafer-start upside is "limited" per fintwit read-throughs.
The stock has tripled off the $84 2025 low and sits ~6% below its all-time high. Three Q's of record revenue have validated the supercycle, the Street is chasing targets upward (WF $365, Mizuho $380), and momentum/retail/political flows (Gottheimer +335%) are euphoric.
That is precisely the setup that demands discipline: the fundamentals are confirming exactly as the multiple peaks. Per the situational-awareness compute-buildout frame, the secular is real and possibly under-discounted on duration — but the market has already paid for it on price.
Management runs the business on WFE share-of-wallet, installed-base monetization (CSBG), margin structure and the 2028 financial model. Hover any tile. All figures TTM through the Mar-2026 quarter (Q3 FY26) unless noted.
| Quarter | Revenue | Guide Mid | vs Guide | EPS | Cons. | GM% | OM% |
|---|---|---|---|---|---|---|---|
| Q3 FY25 · Mar-25 | $4.72B | $4.65B | Beat | $1.04 | $1.00 | 48.0% | 33.1% |
| Q4 FY25 · Jun-25 | $5.17B | $5.20B | In-line | $1.20 | $1.20 | 50.1% | 33.7% |
| Q1 FY26 · Sep-25 | $5.32B | $5.20B | Beat | $1.20 | $1.16 | 50.4% | 34.4% |
| Q2 FY26 · Dec-25 | $5.35B | $5.20B | Beat | $1.27 | $1.16 | 49.6% | 33.9% |
| Q3 FY26 · Mar-26 | $5.84B | $5.70B | Beat | $1.47 | $1.35 | 49.9% | 35.0% |
| Q4 FY26 · Jun-26 (guide) | $6.6B ±0.4 | — | Guided | $1.65 | — | 50.5% | 36.5% |
Source: Lam 8-K/earnings releases & transcripts (Q3 FY26, 22-Apr-2026). Eight straight beats on revenue and EPS; the franchise has out-shipped WFE by ~27pts in the cycle.
FY24 was the memory-driven air-pocket (revenue −14% to $14.9B). FY25–26 is the AI-led recovery, with the critical feature being that margins inflected structurally higher even as revenue surpassed the prior peak — operating leverage plus mix, not just volume.
Revenue waterfall, FY25 → TTM (+$3.2B, ~+26%). Decomposing the growth: ~+18pts volume (foundry GAA tool shipments at TSMC N2 / Samsung SF2 / Intel 18A, plus a DRAM/HBM surge), ~+5pts mix/price (richer foundry & advanced-packaging ASPs, value-priced Akara/Aether/ALTUS-Halo wins), ~+4pts CSBG installed-base compounding, and roughly flat FX. NAND was a modest drag as wafer-starts stayed below prior-peak even as bit-demand improved.
Margin bridge. Operating margin expanded ~300bps YoY to 35.0%: ~120bps of gross-margin mix (second Malaysia facility ramping, CSBG share, value pricing at technology inflections) plus ~180bps of opex leverage as revenue grew ~26% against R&D up ~12% and SG&A roughly flat. Inventory turns hit 2.9×, the highest in 4+ years. This is high-quality operating leverage — the kind that justifies a premium multiple, just not any multiple.
Three lenses: by segment (Systems vs the CSBG annuity), by device end-market (the foundry/DRAM rotation that is de-risking the old NAND concentration), and by geography (the China step-down). The mix shift toward foundry + recurring is the under-appreciated quality story.
Systems $11.5B (62%) · CSBG $6.9B (38%)
Foundry 54% · DRAM 27% (record) · NAND 12% · Logic 7%
China 34% · Korea 22% · Taiwan 19% · Japan 10% · US 7%
Foundry 35% → 54%. GAA (N2/SF2/18A) is structurally more etch- and ALD-intensive than FinFET and carries higher tool ASPs — this is the highest-quality dollar in the mix.
DRAM 16% → 27% (record). HBM3E/HBM4 require ~3–4× the wafer-starts per GB of standard DRAM; the 1B→1C node transition adds etch/ALD cycles. Lam's Syndion + SABRE-3D own the TSV/packaging step.
NAND 18% → 12%. The old concentration risk has fallen — NAND is recovering off a low base (300+ layer cryo-etch wins) but wafer-start upside is capped near-term. A NAND capex re-acceleration is upside optionality, not in the base.
China 42% → 34% → sub-30%. Mature-node (28nm+) is still licensable; the geographic rotation toward Korea/Taiwan/Japan tracks the advanced-node inflection and is, on balance, a quality-up.
Lam doesn't make lithography — that's ASML's monopoly. Lam owns the subtractive (etch) and additive (deposition) steps, plus the new module categories (dry resist, advanced-packaging plating, molybdenum ALD, backside-power enablement) that the AI roadmap is creating from scratch. Each inflection raises chambers-per-wafer.
Feb-2025 flagship for sub-2nm. First solid-state plasma source (100× faster RF response), sub-angstrom ion-energy control. Tool-of-record for GAA foundry & advanced planar DRAM.
The workhorse predecessor — DRAM, 3D-NAND wordline, foundry logic. Massive CSBG spares/service tail.
Cryogenic etch is the enabling tech for 300+ layer 3D-NAND memory holes (>100:1 aspect ratio). A proprietary Lam moat competitors haven't matched at scale.
Deep-silicon etch for HBM stacking & 2.5D/3D packaging (CoWoS, SoIC). Demand surging with HBM4.
Mo replacing tungsten (~50% lower resistivity) across NAND wordlines & GAA contacts. ALD revenue grew ~50% in 2025 off a $1B base — Lam's fastest-growing line.
Copper plating for advanced-packaging RDL (CoWoS, EMIB, HBM interposers). Near-monopoly in copper TSV fill; tripling toward $3B+ as AI packaging scales.
Conformal atomic-layer high-k for GAA gate stacks (4-sided nanosheet wrap) and advanced DRAM.
Plasma-enhanced CVD across DRAM cell stack, NAND inter-layer dielectric, logic spacers.
Replaces wet spin-coat photoresist with an ALD-deposited metal-organic dry film + dry development. Metal-organic resists absorb 3–5× more EUV photons → lower dose, higher throughput, no line-collapse. Already production tool-of-record at a leading memory maker; compatible with low-NA and high-NA EUV. This pushes Lam into a TAM historically owned by chemical companies (JSR, TOK, Shin-Etsu).
GAA: +15–20% etch & ALD steps per wafer vs FinFET; Lam took ~42% of GAA etch wins. Backside power (BSPDN): TSMC N2P / Intel 18A add ~10–15% more backside etch/dep steps — a market created from zero. Equipment Intelligence / Semiverse / Dextro cobots: AI analytics + digital-twin + automation layered onto the installed base, deepening the CSBG moat.
The structural read. Every leading-edge inflection on the 2026–2030 roadmap — NAND vertical scaling toward 1,000 layers, GAA → CFET, backside power, HBM4 → 3D-DRAM, hybrid bonding — is etch- and deposition-intensive by the physics, while litho-intensity per bit actually falls at several of these nodes. That asymmetry is the core of the Lam bull case: Lam's served available market is guided from the mid-30s toward high-30s percent of WFE precisely because Mo-ALD, dry resist and backside-power add new dollar-content per wafer. The bear's counter is simply that 18× sales already capitalizes all of it.
Five tools companies own leading-edge WFE: ASML (litho monopoly), Applied Materials (deposition breadth), Lam (etch + ALD/ECD), KLA (process control monopoly), Tokyo Electron (etch/coat). It is a rational, high-return oligopoly — but the entire group has re-rated to AI-bubble multiples, which is the key valuation context for LRCX.
| Company | Mkt Cap | EV/Sales | P/E (fwd) | Rev Growth | Op Margin | Div Yld | Moat / Niche |
|---|---|---|---|---|---|---|---|
| Lam · LRCX | $408B | ~18× | ~41× | +26% | 35% | 0.3% | Etch #1, ALD/ECD, packaging |
| Applied Materials · AMAT | $317B | ~10× | ~34× | +11% | 30% | 0.4% | Deposition breadth, epi, PVD |
| KLA · KLAC | $228B | ~17× | ~35× | +24% | 42% | 0.5% | Process-control monopoly |
| ASML · ASML | $654B | ~16× | ~44× | +31% | 35% | 0.5% | EUV / High-NA monopoly |
| Tokyo Electron · 8035 | $92B | ~4.5× | ~25× | +7% | 24% | 1.5% | Etch #2, coat/develop |
Approximate, late-May/early-Jun 2026. LRCX prints the second-richest EV/Sales and second-richest fwd P/E in the group — a premium to its larger, deposition-broader peer AMAT, justified by higher growth & etch leadership but offering little margin of safety. Note TEL trades at a ~3–4× sales discount (Japan listing/FX) and is the relative-value way to play the same etch theme.
Wins: uncontested etch #1 (~2:1 over TEL); near-monopoly in HAR cryo-etch & copper-TSV plating; first-mover in Mo-ALD and EUV dry resist; disproportionate exposure to the 3 fastest inflections (NAND scaling, GAA, packaging).
Exposed: zero litho (cedes ~$25B/yr of WFE to ASML); thin in metrology/inspection (KLA's >50% share); behind AMAT in foundry CVD/PVD/epi; DRAM-capacitor ALD contested by TEL/ASMI.
China overhang: domestic vendors Naura (#6 globally, ~$5.7B '25 rev, guided +35%) and AMEC (etch-focused, +46% guided) are climbing — China's WFE share hit 6.5% and a "50% domestic" procurement mandate threatens the mature-node base. Leading-edge HAR etch remains out of their reach for now.
Lam is one integrated franchise, but a SOTP usefully separates the cyclical Systems business from the recurring CSBG annuity (which deserves a software-like multiple). The exercise reveals there is no hidden value — at normalized multiples the parts sum well below the market cap. The whole trades at a premium to a generous SOTP.
| Component | TTM Rev | EBITDA | Multiple | EV |
|---|---|---|---|---|
| Implied Equity Value | + net cash, ÷ 1.25B shares | |||
At normalized mid-cycle multiples — Systems at 14× EBITDA (cyclical hardware) and the CSBG annuity at a premium 24× EBITDA (recurring, ~100k-chamber installed base) — the parts sum to roughly $172/share, ~47% below spot. This is almost exactly where @goodmoat's published DCF ($170) lands. The gap is the AI re-rate.
Reading the conglomerate (non-)discount. Unlike a true conglomerate, there is no trapped value to unlock here — Systems and CSBG are deeply synergistic (every tool sold seeds decades of CSBG spares/service; the installed base is the moat). The SOTP's purpose is therefore diagnostic, not a catalyst: it quantifies that the market is applying a ~50× blended EBITDA multiple to the entire enterprise. To reconcile to the $326 price you must assume Systems holds ~22× peak EBITDA and CSBG ~32× — i.e., that we are mid-supercycle with no mean-reversion. That can be true for a while in a liquidity-flush, AI-thematic tape; it is not a foundation of safety.
Reverse-engineering the multiple: to justify $326.71 on a 5-yr DCF at a 10.75% WACC (β≈1.45, Rf 4.3%, ERP 5%, net-cash structure), the market is embedding a ~14% revenue CAGR to FY30, terminal operating margin holding ~36%, and an exit EV/EBITDA of ~26× — roughly double the 14× mid-cycle WFE-equipment norm. In other words, the price assumes the supercycle compounds uninterrupted and that semicap multiples never normalize.
Market-implied: ~14% rev CAGR, 36% terminal OM, ~26× exit EV/EBITDA — the richest of the four reference points.
Management (2028 model): $25–27B revenue (~13% CAGR), ~50% GM, 34–35% OM, $6–7 EPS — and the company is already running ahead (Q4 GM guide 50.5%, OM 36.5%).
Sell-side consensus: FY26 rev $23.2B / EPS $5.68; FY27 EPS $7.94; mean PT $313 (below spot), high $385.
Our base case: ~12% normalized CAGR, ~36% OM, exit ~22× — implying ~$300–315. We sit modestly below the market-implied number: the secular is real but the multiple has front-run it. The market is believing an AI-capex-supercycle-without-cyclicality story; we believe the supercycle and disbelieve the "without cyclicality."
Three explicit paths, each with its assumption table. Probability-weighting the trio yields a 12-month target of $313 — fractionally below spot, which is the entire reason the rating is HOLD rather than BUY.
A 2027 digestion year: NAND fails to re-accelerate, China revenue resets sub-25% as domestic share climbs, and semicap multiples de-rate toward historical norms. E falls and the multiple compresses simultaneously — the classic cyclical double-hit.
WFE reaches ~$140B in 2026 and grows again in '27; Lam compounds mid-teens with margin at the high end of the model. The market keeps paying a premium-but-stable multiple. The stock roughly treads water as earnings grow into the valuation — time, not price, does the work.
The situational-awareness case: AGI-scale datacenter buildout drives a multi-year WFE supercycle toward $180–200B. Mo-ALD, Aether dry resist and backside-power lift Lam's SAM into the high-30s%; revenue clears $30B by FY28. This is the Mizuho $380 / bull-of-bulls path.
Grouped by type, scored on probability × impact over a 12–24 month horizon. The dominant risk is not the franchise — it's the collision of a cyclical business with a secular-growth multiple.
| Risk | Type | Prob. | Impact | Mitigant |
|---|---|---|---|---|
| Multiple de-rate (50×→norm) | Market | High | High | Earnings growth into the multiple; net-cash buybacks |
| WFE cyclical digestion year | Market | Med | High | CSBG annuity (38%) cushions the trough |
| China revenue reset / export controls | Regulatory | High | Med | Mature-node still licensable; mix rotating to KR/TW |
| Naura / AMEC domestic share gains | Competitive | Med | Med | Leading-edge HAR etch beyond their reach near-term |
| NAND recovery stalls | Market | Med | Med | DRAM/HBM + foundry now carry the model |
| Customer concentration (TSMC/Samsung/SK/Micron) | Execution | Low | High | Multi-customer, multi-node; tools designed-in for years |
| Memory price / capex air-pocket | Financial | Med | Med | Diversified device exposure post-rotation |
| AI-capex narrative reversal (sentiment) | Market | Med | High | Real bookings/backlog, not just narrative — but multiple is narrative-sensitive |
| Taiwan / geopolitical tail | Geopolitical | Low | High | Unhedgeable; sector-wide, not LRCX-specific |
| High-NA / litho-centric scaling shifts value to ASML | Execution | Low | Med | Etch/dep intensity rising at most nodes; offset by new modules |
A 30-day social-sentiment sweep across Reddit, X/fintwit, Hacker News & GitHub (window: 09 May – 08 Jun 2026). The read: euphoric momentum meeting a small but credible valuation-skeptic camp — which maps precisely onto our HOLD.
Why this matters for positioning. The 30-day signal is the textbook late-stage configuration: fundamentals confirming, price at highs, sentiment euphoric, skeptics dismissed. That is not a sell signal on its own — momentum can persist for quarters in a liquidity-flush AI tape — but it is the regime in which forward risk/reward is least favorable. The single most analytically useful data point in the entire sweep is the convergence of an independent retail DCF (@goodmoat, $170) with our own normalized SOTP ($172) and the CFO's realized selling zone ($224–230). When three independent methods cluster ~45% below spot, the burden of proof sits squarely on the multiple, not the franchise.
Guide was $6.6B / $1.65 EPS / 50.5% GM / 36.5% OM. The market needs the initial FY27 WFE commentary ("setting up to be a pretty good year") to be ratified. Any hint of '27 digestion is the de-rate trigger.
Each tightening or domestic-mandate headline pressures the ~34% China base and feeds the Naura/AMEC share narrative.
SK Hynix/Samsung/Micron HBM4 and TSMC packaging capacity directly pull Syndion + SABRE-3D.
The +15–20% etch/ALD-intensity step-up converts to revenue as 2nm goes to true HVM across three foundries.
Second/third tool-of-record wins validate the $1.5B Aether TAM and the SAM-expansion thesis.
A genuine NAND wafer-start cycle (vs today's bit-demand-only recovery) is the largest un-modeled upside. Watch hyperscaler storage + 500-layer transitions.
The largest future driver of etch intensity in memory — Lam's core physics advantage compounds.
New from-zero etch/dep modules at every advanced-logic fab; "billion-dollar-plus" per management.
Already tracking ahead on margin. The real question is the multiple the market assigns to the achievement.
Data sources & timestamp. Price & financial statements via Yahoo Finance (last close $326.71, 08-Jun-2026; cross-checked vs Kraken/CompaniesMarketCap/TradingEconomics at $382–420B cap). Fundamentals: Lam 10-K FY25, 8-Ks & transcripts through Q3 FY26 (22-Apr-2026). Consensus/ownership: StockAnalysis, MarketBeat, Insider Monkey, GuruFocus. Competitive/WFE data: SEMI, TechInsights, TrendForce, company filings. Sentiment: 30-day social-sentiment sweep (Reddit/X/HN/GitHub, 09-May–08-Jun-2026). Macro framing per the situational-awareness compute-buildout worldview. Multiples computed from the $408B market cap and TTM figures; peer multiples approximate. Figures are estimates where labeled; the entire semicap group trades at elevated AI-cycle multiples, which is the central valuation context.
Prepared by Jeff — institutional equity research, for a sophisticated buy-side reader. Analyst-grade thinking, not regulated investment advice.